SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Piper Jaffray Healthcare Conference on Tuesday, November 27, at 12:30 p.m. EST in New York.
A live webcast of the presentation can be accessed on the company’s website at www.pellepharm.com. A replay of the webcast will be archived on the PellePharm website for at least two weeks following the presentation.
About PellePharm
Founded by world leaders in hedgehog
pathway signaling, PellePharm, a BridgeBio Company, is committed to
targeting rare, genetic dermatological diseases, including Gorlin
Syndrome and High Frequency Basal Cell Carcinoma (BCC), at their source.
PellePharm’s mission is to improve the quality of life for those
suffering from Gorlin Syndrome and High Frequency BCC by providing an
easy-to-use topical gel that eliminates the need for regular, painful
surgeries. Patidegib topical gel is a first-in-class topical formulation
of a proprietary hedgehog inhibitor.
